| Dr Justin R Knapp, MD | |
|
130 Fisher Rd, Berlin, VT 05602-9516 | |
| (802) 371-4316 | |
| (802) 371-4579 |
| Full Name | Dr Justin R Knapp |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 20 Years |
| Location | 130 Fisher Rd, Berlin, Vermont |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336242528 | NPI | - | NPPES |
| 1023012 | Medicaid | VT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 51706-20 (Wisconsin) | Secondary |
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 042.0012862 (Vermont) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Central Vermont Medical Center | Barre, VT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Vermont Medical Center Inc | 9335138817 | 204 |
| Washington County Mental Health Services Inc | 8123010121 | 18 |
News Archive
The Parenteral Drug Association (PDA) proudly announces that it will be a supporting organization of the Johnson & Johnson Kilmer Conference on sterility assurance and sterilization in 2016.
New research suggests that administering taurine, a molecule naturally produced by human cells, could boost the effectiveness of current multiple sclerosis (MS) therapies.
Galenea Corp. has been awarded a highly competitive grant from the National Institute of Mental Health in response to the solicitation "Recovery Act Limited Competition: NIH Director's Opportunity for Research in Five Thematic Areas (RC4)," funded by the American Recovery and Reinvestment Act of 2009. Galenea has developed an innovative technology platform, termed MANTRA™ (Multiwell, Automated NeuroTRansmission Assay) that enables high-throughput screening for the identification of small molecule modulators of synaptic transmission.
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.
Jim Greenwood, president and CEO of the Biotechnology Industry Organization (BIO), has issued the following statement on H.R. 3, the Stem Cell Research Enhancement Act of 2007.
› Verified 2 days ago
| Entity Name | University Of Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659309615 PECOS PAC ID: 3779491071 Enrollment ID: O20040406001047 |
News Archive
The Parenteral Drug Association (PDA) proudly announces that it will be a supporting organization of the Johnson & Johnson Kilmer Conference on sterility assurance and sterilization in 2016.
New research suggests that administering taurine, a molecule naturally produced by human cells, could boost the effectiveness of current multiple sclerosis (MS) therapies.
Galenea Corp. has been awarded a highly competitive grant from the National Institute of Mental Health in response to the solicitation "Recovery Act Limited Competition: NIH Director's Opportunity for Research in Five Thematic Areas (RC4)," funded by the American Recovery and Reinvestment Act of 2009. Galenea has developed an innovative technology platform, termed MANTRA™ (Multiwell, Automated NeuroTRansmission Assay) that enables high-throughput screening for the identification of small molecule modulators of synaptic transmission.
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.
Jim Greenwood, president and CEO of the Biotechnology Industry Organization (BIO), has issued the following statement on H.R. 3, the Stem Cell Research Enhancement Act of 2007.
› Verified 2 days ago
| Entity Name | Central Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831374362 PECOS PAC ID: 9335138817 Enrollment ID: O20040510001034 |
News Archive
The Parenteral Drug Association (PDA) proudly announces that it will be a supporting organization of the Johnson & Johnson Kilmer Conference on sterility assurance and sterilization in 2016.
New research suggests that administering taurine, a molecule naturally produced by human cells, could boost the effectiveness of current multiple sclerosis (MS) therapies.
Galenea Corp. has been awarded a highly competitive grant from the National Institute of Mental Health in response to the solicitation "Recovery Act Limited Competition: NIH Director's Opportunity for Research in Five Thematic Areas (RC4)," funded by the American Recovery and Reinvestment Act of 2009. Galenea has developed an innovative technology platform, termed MANTRA™ (Multiwell, Automated NeuroTRansmission Assay) that enables high-throughput screening for the identification of small molecule modulators of synaptic transmission.
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.
Jim Greenwood, president and CEO of the Biotechnology Industry Organization (BIO), has issued the following statement on H.R. 3, the Stem Cell Research Enhancement Act of 2007.
› Verified 2 days ago
| Entity Name | Washington County Mental Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922026996 PECOS PAC ID: 8123010121 Enrollment ID: O20040519000738 |
News Archive
The Parenteral Drug Association (PDA) proudly announces that it will be a supporting organization of the Johnson & Johnson Kilmer Conference on sterility assurance and sterilization in 2016.
New research suggests that administering taurine, a molecule naturally produced by human cells, could boost the effectiveness of current multiple sclerosis (MS) therapies.
Galenea Corp. has been awarded a highly competitive grant from the National Institute of Mental Health in response to the solicitation "Recovery Act Limited Competition: NIH Director's Opportunity for Research in Five Thematic Areas (RC4)," funded by the American Recovery and Reinvestment Act of 2009. Galenea has developed an innovative technology platform, termed MANTRA™ (Multiwell, Automated NeuroTRansmission Assay) that enables high-throughput screening for the identification of small molecule modulators of synaptic transmission.
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.
Jim Greenwood, president and CEO of the Biotechnology Industry Organization (BIO), has issued the following statement on H.R. 3, the Stem Cell Research Enhancement Act of 2007.
› Verified 2 days ago
| Entity Name | Central Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023028784 PECOS PAC ID: 9335138817 Enrollment ID: O20051220000393 |
News Archive
The Parenteral Drug Association (PDA) proudly announces that it will be a supporting organization of the Johnson & Johnson Kilmer Conference on sterility assurance and sterilization in 2016.
New research suggests that administering taurine, a molecule naturally produced by human cells, could boost the effectiveness of current multiple sclerosis (MS) therapies.
Galenea Corp. has been awarded a highly competitive grant from the National Institute of Mental Health in response to the solicitation "Recovery Act Limited Competition: NIH Director's Opportunity for Research in Five Thematic Areas (RC4)," funded by the American Recovery and Reinvestment Act of 2009. Galenea has developed an innovative technology platform, termed MANTRA™ (Multiwell, Automated NeuroTRansmission Assay) that enables high-throughput screening for the identification of small molecule modulators of synaptic transmission.
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.
Jim Greenwood, president and CEO of the Biotechnology Industry Organization (BIO), has issued the following statement on H.R. 3, the Stem Cell Research Enhancement Act of 2007.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Justin R Knapp, MD Po Box 547, Att: Cvmc Finance Dept, Barre, VT 05641-0547 Ph: (802) 371-4316 | Dr Justin R Knapp, MD 130 Fisher Rd, Berlin, VT 05602-9516 Ph: (802) 371-4316 |
News Archive
The Parenteral Drug Association (PDA) proudly announces that it will be a supporting organization of the Johnson & Johnson Kilmer Conference on sterility assurance and sterilization in 2016.
New research suggests that administering taurine, a molecule naturally produced by human cells, could boost the effectiveness of current multiple sclerosis (MS) therapies.
Galenea Corp. has been awarded a highly competitive grant from the National Institute of Mental Health in response to the solicitation "Recovery Act Limited Competition: NIH Director's Opportunity for Research in Five Thematic Areas (RC4)," funded by the American Recovery and Reinvestment Act of 2009. Galenea has developed an innovative technology platform, termed MANTRA™ (Multiwell, Automated NeuroTRansmission Assay) that enables high-throughput screening for the identification of small molecule modulators of synaptic transmission.
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.
Jim Greenwood, president and CEO of the Biotechnology Industry Organization (BIO), has issued the following statement on H.R. 3, the Stem Cell Research Enhancement Act of 2007.
› Verified 2 days ago
Peter M Thomashow, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 130 Fisher Rd, Central Vermont Medical Center, Berlin, VT 05602 Phone: 802-371-4316 Fax: 802-371-4579 | |
Jessica E O'neil, D.O. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 286 Hospital Loop, Berlin, VT 05602 Phone: 802-229-0591 Fax: 802-223-3667 | |
Dr. Ryosuke Kawatsuji, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 130 Fisher Rd, Central Vermont Medical Center, Berlin, VT 05602 Phone: 802-371-4100 | |
Kenneth Elliot Adler, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 130 Fisher Rd, Berlin, VT 05602 Phone: 802-371-4100 | |
Brian Joseph Rosen, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 130 Fisher Rd, Berlin, VT 05602 Phone: 802-371-4100 | |
Nicholas Phillips, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 130 Fisher Rd, Berlin, VT 05602 Phone: 802-371-4100 |